TerminatedPhase 1NCT01339039

Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma

Studying Anaplastic astrocytoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Patrick Y. Wen, MD
Principal Investigator
Patrick Y. Wen, MD
Dana-Farber Cancer Institute
Intervention
Plerixafor(drug)
Enrollment
26 enrolled
Eligibility
18 years · All sexes
Timeline
20112017

Study locations (2)

Collaborators

Dana-Farber Cancer Institute · Brigham and Women's Hospital · Massachusetts General Hospital · Genzyme, a Sanofi Company

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01339039 on ClinicalTrials.gov

Other trials for Anaplastic astrocytoma

Additional recruiting or active studies for the same condition.

See all trials for Anaplastic astrocytoma

← Back to all trials